Analyst Price Target is $5.63
▲ +225.14% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for DBV Technologies in the last 3 months. The average price target is $5.63, with a high forecast of $10.00 and a low forecast of $1.50. The average price target represents a 225.14% upside from the last price of $1.73.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in DBV Technologies. This rating has held steady since July 2022, when it changed from a Hold consensus rating.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.